CLARINET study in metastatic enteropancreatic neuroendocrine tumours

A strong anti-proliferative response was demonstrated for the somatostatin analogue lanreotide in patients with gastroenteropancreatic neuro-endocrine tumours. The final analyses of data from a phase III trial showed that treatment with lanreotide significantly prolonged progression-free survival in patients with gastroenteropancreatic neuroendocrine tumours compared to treatment with placebo. The results presented by lead investigator Dr. Martyn Caplin, Professor of Gastroenterology & Gastrointestinal Neuroendocrinology, Royal Free Hospital, London, UK, last year have now been published in the New England Journal of Medicine. Read more here.